The upgrade in the price target by a reputable analyst like David Hoang from Citigroup is a strong positive signal for Sarepta Therapeutics. It suggests confidence in the company's future performance and potential for stock price appreciation. This kind of endorsement typically leads to increased investor interest and can drive the stock price up in the short term.